Akribion Therapeutics

Akribion Therapeutics is a company headquartered in Germany. Brouky classifies it under Healthcare & Life Sciences.

Akribion Therapeutics develops an RNA-guided, nuclease-based platform technology for programmable cell depletion by using its G-dase® E payload to selectively kill target cells through DNA and RNA shredding, initially focusing on HPV-induced oropharyngeal head and neck cancer and exploring uses in oncology, autoimmune, fibrosis, and infectious diseases.